Multidrug resistant Klebsiella pneumoniae which carries blaNDM-1 and blaKPC-2 genes is a worldwide concern and combination antimicrobial therapy may be the only viable option. Therefore, the aim of this study was to investigate in vitro activity of combinations of polymyxin B (PMB) with meropenem (MEM), amikacin (AMK) and gentamicin (GEN) in subinhibitory concentrations against two clinical isolates of blaNDM-1, blaKPC-2 and AMEs and resistant to polymyxin B. In this study, synergy and bactericidal activity were evaluated by checkerboard and time-kill, against two clinical isolates of polymyxin B-resistant K. pneumoniae which are resistant to polymyxin B (PMB) and are carriers of the blaNDM-1, blaKPC-2, aac(3)-IIa, aac(6)-Ib aph(3)-VI and ant(2)-Ia genes. Five combinations using the antimicrobials polymyxin B, meropenem (MEM), amikacin (AMK) and gentamicin (GEN) were evaluated. The PMB / MEM and PMB / AMK combinations proved to be the best options against the K7R2 isolate, mainly because they demonstrated bactericidal activity when using subinhibitory concentrations of these antimicrobials. However, none of the studied combinations were bactericidal against the K11R2 isolate. In conclusion, the combinations used in this study showed synergy against NDM and KPC producing isolates, but, given the bactericidal activity, the combinations of PMB / MEM and PMB / AMK were the most active only against one isolate. It also can be concluded that the antimicrobials to which the bacteria were resistant could be part of these combinations.